A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

June 3, 2026 updated by: AbbVie

Assessment of the Relative Bioavailability of ABBV-932 Formulations in Healthy Adult Subjects

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Illinois
      • Grayslake, Illinois, United States, 60030
        • Acpru /Id# 266649

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

Exclusion Criteria:

  • History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ABBV-932: Arm A
Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet
Experimental: ABBV-932: Arm B
Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet
Experimental: ABBV-932: Arm C
Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet
Experimental: ABBV-932: Arm D
Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet
Experimental: ABBV-932: Arm E
Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet
Experimental: ABBV-932: Arm F
Participants will receive a single dose of ABBV-932 Arm F on day 1 under fasting conditions.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet
Experimental: ABBV-932: Arm G
Participants will receive a single dose of ABBV-932 Arm G on day 1 with a high-fat meal.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet
Experimental: ABBV-932: Arm H
Participants will receive a single dose of ABBV-932 Arm H on day 1 under fasting conditions.
Drug: ABBV-932
Oral Capsule
Drug: ABBV-932
Oral tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Plasma Concentration (Cmax) of ABBV-932
Time Frame: Up to approximately 6 days
Cmax of ABBV-932
Up to approximately 6 days
Time to Cmax (Tmax) of ABBV-932
Time Frame: Up to approximately 6 days
Tmax of ABBV-932
Up to approximately 6 days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-932
Time Frame: Up to approximately 6 days
Terminal phase elimination rate constant (beta) of ABBV-932
Up to approximately 6 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-932
Time Frame: Up to approximately 6 days
Terminal phase elimination half-life of ABBV-932
Up to approximately 6 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932
Time Frame: Up to approximately 6 days
AUCt of ABBV-932
Up to approximately 6 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932
Time Frame: Up to approximately 6 days
AUCinf of ABBV-932
Up to approximately 6 days
Number of Participants Experiencing Adverse Events
Time Frame: Up to approximately 180 days
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Up to approximately 180 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AbbVie

Investigators

  • Study Director: ABBVIE INC., AbbVie

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 26, 2025

Primary Completion (Actual)

May 8, 2026

Study Completion (Actual)

May 8, 2026

Study Registration Dates

First Submitted

February 24, 2025

First Submitted That Met QC Criteria

February 24, 2025

First Posted (Actual)

February 27, 2025

Study Record Updates

Last Update Posted (Actual)

June 4, 2026

Last Update Submitted That Met QC Criteria

June 3, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • M24-889

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteer

Clinical Trials on ABBV-932

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe